AR031857A1 - Pirroloquinolonas, composiciones farmaceuticas, uso de las mismas para preparar un medicamento antiviral y un metodo para producir un intermediario - Google Patents
Pirroloquinolonas, composiciones farmaceuticas, uso de las mismas para preparar un medicamento antiviral y un metodo para producir un intermediarioInfo
- Publication number
- AR031857A1 AR031857A1 ARP010103208A ARP010103208A AR031857A1 AR 031857 A1 AR031857 A1 AR 031857A1 AR P010103208 A ARP010103208 A AR P010103208A AR P010103208 A ARP010103208 A AR P010103208A AR 031857 A1 AR031857 A1 AR 031857A1
- Authority
- AR
- Argentina
- Prior art keywords
- heterocycle
- alkyl
- cycloalkyl
- aryl
- substituted
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000000840 anti-viral effect Effects 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 17
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 14
- 125000003118 aryl group Chemical group 0.000 abstract 14
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 229910052736 halogen Inorganic materials 0.000 abstract 10
- 150000002367 halogens Chemical class 0.000 abstract 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- -1 OR11 Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052744 lithium Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 150000002923 oximes Chemical class 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Chemical group 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- WUKKREVJKMPFTB-UHFFFAOYSA-N pyrrolo[2,3-h]quinolin-2-one Chemical class C1=C2N=CC=C2C2=NC(=O)C=CC2=C1 WUKKREVJKMPFTB-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Pirroloquinolonas, que comprenden un compuesto de formula (1) o un derivado de la misma que sea una sal, racemato, solvato, tautomero, isomero optico o prodroga farmacéuticamente aceptable, donde: R1 es F, Cl, Br, CN, o NO2; R2 y R3 son independientemente, H, halogeno, OR11, C(=O)R7, C(=O)OR11, cicloalquilo C3-8, o alquilo C1-7 que podría estar parcialmente insaturado y opcionalmente sustituido por uno o más halogenos, cicloalquilo C3-8, R12, OR14, SR11, SR14, NR8R9, NR11C(O)R7, (C=O)alquilo C1-7 o SOmR10; R4 y R5 son independientemente, H, halogeno, arilo, S(O)mR7, (C=O)R7, (C=O)OR10, CN, heterociclo, donde dicho heterociclo está unido por un átomo de C, OR11, heterociclo O, NR8R9, SR11, heterociclo S, NHCOR13, NHSO2R13, cicloalquilo C3-8, o alquilo C1-7 que podría estar parcialmente insaturado o sustituido por uno o más R12, OR14, SR11, SR14, NR8R9, halogeno, cicloalquilo C3-8, (C=O)alquilo C1-7 o SOmR10; R6 es H, halogeno, cicloalquilo C3-8, o alquilo C1-4 opcionalmente sustituido por 1-3 halogenos; R7 es alquilo C1-7, cicloalquilo C3-8, NR8R9, arilo, o heterociclo, donde dicho heterociclo está unido por un átomo de C; R8 y R9 son independientemente, H, arilo, cicloalquilo C3-8, alquilo C1-7 que podría estar parcialmente insaturado o sustituido por uno o más NR11R11, R12, SOmR10, CONR11R11, OH, arilo, heterociclo, cicloalquilo C3-8 o halogeno, o R8 y R9 junto con el nitrogeno al cual están unidos para un heterociclo; R10 es arilo, heterociclo, cicloalquilo C3-8, o alquilo C1-7 que podría estar parcialmente insaturado o sustituido por uno o más NR11R11, R12, SH, CONR11R11, cicloalquilo C3-8, o halogeno; R11 es H, arilo, cicloalquilo C3-8, o alquilo C1-7 opcionalmente sustituido por OH; R12 es OR11, heterociclo O, arilo O, CO2R11, heterociclo, arilo, o CN; R13 es H, heterociclo, arilo, cicloalquilo C3-8, o alquilo C1-7 opcionalmente sustituido por NR11R11 o R12; R14 es (P=O)(OR15)2, CO(CH2)nCON(CH3)-(CH2)nSO3-M+, un aminoácido, C(=O)arilo, o C(=O)alquilo C1-7, que podría sustituirse por NR11R11, arilo, heterociclo, CO2H o O(CH2)nCO2R15; R15 es H o alquilo C1-7; arilo es un radical fenilo o un radical orto-unido bicíclico carbocíclico donde al menos un anillo es aromático; cada vez, el arilo puede sustituirse con uno o más halogenos, CN, CO2R11, SR11, OR11, NR11R11, alquilo C1-4, CF3 o cicloalquilo C3-8; heterociclo es un anillo heterocíclico saturado o insaturado de 4, 5, 6 o 7 miembros con 1, 2, o 3 heteroátomos seleccionados del grupo integrado por O, SOm y NX; donde X es H, alquilo C1-4 o ausente en el que el heterociclo está opcionalmente unido a un anillo bencénico o a cualquier grupo heterocíclico bicíclico; cada vez el heterociclo también puede estar sustituido con uno o más halogenos, CN, CO2R11, SR11, OR11, NR11R11, C(=O)R12, alquilo C1-4, CF3, cicloalquilo C3-8, oxo u oxima; cada vez, m es independientemente 0, 1 o 2; cada vez, n es independientemente 1, 2, 3, 4, 5 o 6; y M es sodio, potasio o litio; composicion farmacéutica, uso de las mismas para preparar en particular, como agente contra virus de la familia herpes un medicamento antiviral, y un método para producir un intermediario.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21598600P | 2000-07-05 | 2000-07-05 | |
| US27701201P | 2001-03-19 | 2001-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031857A1 true AR031857A1 (es) | 2003-10-08 |
Family
ID=26910543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103208A AR031857A1 (es) | 2000-07-05 | 2001-07-05 | Pirroloquinolonas, composiciones farmaceuticas, uso de las mismas para preparar un medicamento antiviral y un metodo para producir un intermediario |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6525049B2 (es) |
| EP (1) | EP1299386A1 (es) |
| JP (1) | JP2004502689A (es) |
| KR (1) | KR20030014320A (es) |
| CN (1) | CN1437600A (es) |
| AR (1) | AR031857A1 (es) |
| AU (1) | AU2001271258A1 (es) |
| CA (1) | CA2410658A1 (es) |
| MX (1) | MXPA03000107A (es) |
| MY (1) | MY117789A (es) |
| NZ (1) | NZ523449A (es) |
| PE (1) | PE20020193A1 (es) |
| TW (1) | TW593316B (es) |
| WO (1) | WO2002002558A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040102473A1 (en) * | 2002-08-30 | 2004-05-27 | Wathen Michael W. | Method of preventing or treating atherosclerosis or restenosis |
| CA2537325A1 (en) | 2003-09-19 | 2005-03-31 | Gilead Sciences, Inc. | Aza-quinolinol phosphonate integrase inhibitor compounds |
| WO2005117904A2 (en) * | 2004-04-14 | 2005-12-15 | Gilead Sciences, Inc. | Phosphonate analogs of hiv integrase inhibitor compounds |
| DE102006005861A1 (de) * | 2006-02-09 | 2007-08-23 | Aicuris Gmbh & Co. Kg | Substituierte Chinolone III |
| AU2008240764C1 (en) * | 2007-04-20 | 2011-10-20 | Glaxo Group Limited | Tricyclic nitrogen containing compounds as antibacterial agents |
| US9290476B2 (en) | 2012-10-16 | 2016-03-22 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| CN105073729A (zh) | 2012-10-16 | 2015-11-18 | 詹森药业有限公司 | RORγt的苯基连接的喹啉基调节剂 |
| CN104884448A (zh) | 2012-10-16 | 2015-09-02 | 詹森药业有限公司 | Rorγt的杂芳基连接的喹啉基调节剂 |
| BR112016008258A2 (pt) | 2013-10-15 | 2017-10-10 | Janssen Pharmaceutica Nv | moduladores de ror?t de quinolinila |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| BR112016008215A2 (pt) | 2013-10-15 | 2017-09-26 | Janssen Pharmaceutica Nv | moduladores de quinolinila ligados por alquila de roryt |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| CA3112326A1 (en) | 2018-09-12 | 2020-03-19 | Novartis Ag | Antiviral pyridopyrazinedione compounds |
| KR20250127350A (ko) | 2019-09-26 | 2025-08-26 | 노파르티스 아게 | 항바이러스성 피라졸로피리디논 화합물 |
| CN111349094B (zh) * | 2020-04-23 | 2021-02-02 | 杭州师范大学 | 一种6H-咪唑[4,5,1-ij]并喹诺酮及其合成方法和应用 |
| CN112349961B (zh) * | 2020-11-12 | 2021-09-24 | 宁德新能源科技有限公司 | 电解液及包含其的电化学装置和电子设备 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3917609A (en) | 1973-06-27 | 1975-11-04 | Minnesota Mining & Mfg | Pyrroloquinoline carboxylic acids and derivatives |
| DE2914218C2 (de) | 1978-04-12 | 1985-10-24 | Otsuka Pharmaceutical Co. Ltd., Tokio/Tokyo | N-Acylderivate des Ampicillins und Amoxicillins, Verfahren zu deren Herstellung und pharmazeutische Zubereitungen, welche die Verbindungen enthalten |
| JPS55145612A (en) | 1979-05-02 | 1980-11-13 | Otsuka Pharmaceut Co Ltd | Anti-bacterial agent |
| JPS55153792A (en) | 1979-05-18 | 1980-11-29 | Otsuka Pharmaceut Co Ltd | Cephalosporanic acid derivative |
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| JPH0262875A (ja) | 1988-05-23 | 1990-03-02 | Wakunaga Pharmaceut Co Ltd | 新規イソインドリン誘導体 |
| GB2236751B (en) | 1989-10-14 | 1993-04-28 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| GB9108547D0 (en) | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| EP0775702B1 (en) | 1994-08-12 | 2003-07-23 | Toyama Chemical Co., Ltd. | Novel quinolone- or naphthyridonecarboxylic acid derivative or salt thereof |
| US5792774A (en) * | 1996-02-21 | 1998-08-11 | Chiroscience Limited | Quinolones and their therapeutic use |
| CA2241891A1 (en) | 1996-02-21 | 1997-08-21 | Darwin Discovery Limited | Quinolones and their therapeutic use |
| WO1997030999A1 (en) | 1996-02-21 | 1997-08-28 | Darwin Discovery Limited | Quinolones and their therapeutic use |
| PL341364A1 (en) | 1997-12-22 | 2001-04-09 | Upjohn Co | 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents |
| ITMI981670A1 (it) * | 1998-07-21 | 2000-01-21 | Zambon Spa | Derivati ftalazinici inibitori della fosfodiesterasi 4 |
| US6248739B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
-
2001
- 2001-06-22 US US09/888,283 patent/US6525049B2/en not_active Expired - Fee Related
- 2001-06-25 CN CN01811360A patent/CN1437600A/zh active Pending
- 2001-06-25 EP EP01950235A patent/EP1299386A1/en not_active Withdrawn
- 2001-06-25 JP JP2002507810A patent/JP2004502689A/ja active Pending
- 2001-06-25 KR KR10-2003-7000127A patent/KR20030014320A/ko not_active Withdrawn
- 2001-06-25 CA CA002410658A patent/CA2410658A1/en not_active Abandoned
- 2001-06-25 WO PCT/US2001/016493 patent/WO2002002558A1/en not_active Ceased
- 2001-06-25 NZ NZ523449A patent/NZ523449A/en unknown
- 2001-06-25 MX MXPA03000107A patent/MXPA03000107A/es not_active Application Discontinuation
- 2001-06-25 AU AU2001271258A patent/AU2001271258A1/en not_active Abandoned
- 2001-06-26 MY MYPI20013011A patent/MY117789A/en unknown
- 2001-07-03 PE PE2001000659A patent/PE20020193A1/es not_active Application Discontinuation
- 2001-07-05 TW TW090116504A patent/TW593316B/zh not_active IP Right Cessation
- 2001-07-05 AR ARP010103208A patent/AR031857A1/es not_active Application Discontinuation
-
2002
- 2002-11-05 US US10/288,117 patent/US6683181B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03000107A (es) | 2003-08-19 |
| EP1299386A1 (en) | 2003-04-09 |
| TW593316B (en) | 2004-06-21 |
| AU2001271258A1 (en) | 2002-01-14 |
| CA2410658A1 (en) | 2002-01-10 |
| US6525049B2 (en) | 2003-02-25 |
| NZ523449A (en) | 2004-09-24 |
| JP2004502689A (ja) | 2004-01-29 |
| CN1437600A (zh) | 2003-08-20 |
| US20030153561A1 (en) | 2003-08-14 |
| KR20030014320A (ko) | 2003-02-15 |
| US20020055636A1 (en) | 2002-05-09 |
| MY117789A (en) | 2004-08-30 |
| WO2002002558A1 (en) | 2002-01-10 |
| US6683181B2 (en) | 2004-01-27 |
| PE20020193A1 (es) | 2002-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031857A1 (es) | Pirroloquinolonas, composiciones farmaceuticas, uso de las mismas para preparar un medicamento antiviral y un metodo para producir un intermediario | |
| AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| AR039659A1 (es) | Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa | |
| ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
| AR030243A1 (es) | Carboxamidas heterociclicas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento antiviral y metodo in vitro para inhibir el adn polimerasa viral | |
| CO5251381A1 (es) | Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR035069A1 (es) | Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento | |
| AR038814A1 (es) | Compuestos de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-ona y uso en la fabricacion de medicamentos | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR030249A1 (es) | Peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c, composicion farmaceutica que lo comprende, un metodo para su preparacion y el uso de los mismos para la manufactura de medicamentos y un metodo para modular el procesamiento de un polipeptido del virus | |
| AR037329A1 (es) | Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| AR010376A1 (es) | Compuestos con efecto analgesico, su uso para la fabricacion de medicamentos, agentes de diagnostico, composicion farmaceutica, procedimiento para la preparacion de dichos compuestos y compuestos intermediarios | |
| AR036032A1 (es) | Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif | |
| AR084768A1 (es) | Moduladores de la senda de complemento y usos de los mismos | |
| AR040806A1 (es) | Derivados de piperidi-2-ona 1,6 disustituidos, composicion farmaceutica que la comprende y metodo de tratamiento | |
| AR043049A1 (es) | Derivados de hidantoina, proceso de preparacion del mismo y composicion farmaceutica | |
| AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
| AR030304A1 (es) | Oxazinquinolonas, composiciones farmaceuticas que las comprenden y uso de las mismas para preparar un medicamento util en el tratamiento de infecciones virales | |
| AR048789A1 (es) | Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
| AR035254A1 (es) | Derivados fluorquinolonicos de oxazolidinonas utiles como antibacterianos, procedimiento para su obtencion y su utilizacion para la preparacion de una composicion farmaceutica | |
| SE0201937D0 (sv) | Therapeutic agents | |
| UY27803A1 (es) | Derivados de benzoxazina y usos de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |